WGU D398 INTRODUCTION TO PHARMACOLOGY OA STUDY
BUNDLE | QUESTIONS & ANSWERS WITH RATIONALES, V1-V3,
DRUG TABLES, DOSAGE CALCULATIONS & 2 MOCK EXAMS
210 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
WGU D398 INTRODUCTION TO PHARMACOLOGY OA STUDY BUNDLE | QUESTIONS & ANSWERS WITH
RATIONALES, V1-V3, DRUG TABLES, DOSAGE CALCULATIONS & 2 MOCK EXAMS. It contains 210 carefully
selected questions that reflect the most current exam content and testing strategies. Each question is
accompanied by a correct answer and a detailed rationale that explains the underlying pathophysiology,
pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 210 Questions
Foundations - Application - WGU D398 Introduction TO Pharmacology OA Study Bundle & WITH
Rationales V1 V3 DRUG Tables Dosage Calculations & 2 Exams WGU D398 Introduction TO Pharmacology
OA Study Bundle & WITH Rationales V1 V3 DRUG Tables Dosage Calculations & 2 Exams University
All answers with rationales
,Table of Contents
Content Area Questions Key Topics
Pharmacokinetics AND 1-35 Prescribed, Likely, Warfarin, Effect, Receiving
Pharmacodynamics
Autonomic Nervous System 36-70 Appropriate, Mechanism, Diabetes, Develops, Prescribed
Drugs
Cardiovascular AND Renal 71-105 Mechanism, Effect, Prescribed, Likely, Ratio
Drugs
Central Nervous System 106-140 Prescribed, Effect, Digoxin, Mechanism, Laboratory
Drugs
Endocrine Drugs 141-175 Effect, Prescribed, Concentration, Likely, Phenytoin
Antimicrobials AND 176-210 Likely, Develops, Explains, Mechanism, Adverse
Anti-infectives
TOTAL 210 All questions include answers and detailed rationales
,Section A - Pharmacokinetics AND Pharmacodynamics
Q1.
A patient on an SSRI for major depression develops serotonin syndrome after adding
linezolid. Which pharmacodynamic principle best explains this interaction?
A. Competitive antagonism at 5-HT3 B. Irreversible inhibition of monoamine
receptors oxidase leading to excess synaptic
serotonin
C. Cytochrome P450 2D6 inhibition D. Displacement of serotonin from plasma
increasing SSRI levels proteins
Correct: B - Irreversible inhibition of monoamine oxidase leading to excess synaptic
serotonin
Rationale:Linezolid is a reversible, nonselective MAO inhibitor that decreases serotonin
metabolism, and when combined with an SSRI, it can precipitate serotonin syndrome. This is
a pharmacodynamic interaction at the enzyme level, not receptor antagonism or
pharmacokinetic CYP inhibition. Protein binding displacement is not a significant mechanism
for this interaction.
Q2.
A prescriber orders a loading dose of digoxin followed by maintenance therapy. Which
pharmacokinetic parameter is most critical to calculate the loading dose?
A. Clearance B. Volume of distribution
C. Half-life D. Bioavailability
Correct: B - Volume of distribution
Rationale:The loading dose is calculated as target concentration multiplied by volume of
distribution divided by bioavailability. Clearance and half-life determine maintenance dosing
and time to steady state, not the initial loading dose. Bioavailability is a modifier but not the
primary determinant.
Q3.
A patient with opioid-induced constipation is prescribed methylnaltrexone. Which
property of this drug makes it peripherally selective?
A. It is a highly lipophilic agonist that B. It is a quaternary amine that poorly
crosses the blood-brain barrier penetrates the central nervous system
C. It is a prodrug activated only in the gut D. It is a substrate for P-glycoprotein efflux
in the brain
Page 3
, Section A - Pharmacokinetics AND Pharmacodynamics
Correct: B - It is a quaternary amine that poorly penetrates the central nervous system
Rationale:Methylnaltrexone is a quaternary ammonium compound with low lipophilicity,
limiting CNS penetration, thus it antagonizes peripheral opioid receptors without reversing
analgesia. It is not an agonist, not a prodrug, and P-glycoprotein is not the primary
mechanism.
Q4.
A patient on warfarin requires a course of an antibiotic. Which antibiotic is most likely to
increase warfarin's anticoagulant effect through inhibition of CYP2C9?
A. Azithromycin B. Ciprofloxacin
C. Metronidazole D. Cephalexin
Correct: C - Metronidazole
Rationale:Metronidazole is a potent inhibitor of CYP2C9, the enzyme that metabolizes
S-warfarin, leading to increased INR and bleeding risk. Ciprofloxacin inhibits CYP1A2 and
3A4, but its effect on warfarin is less pronounced. Azithromycin has minimal CYP inhibition,
and cephalexin is not known to interact significantly.
Q5.
A patient with type 2 diabetes is prescribed canagliflozin. Which mechanism of action is
correct for this drug?
A. Increases insulin secretion from B. Inhibits sodium-glucose cotransporter 2 in
pancreatic beta cells the proximal tubule
C. Activates peroxisome D. Decreases hepatic glucose production by
proliferator-activated receptor gamma activating AMP kinase
Correct: B - Inhibits sodium-glucose cotransporter 2 in the proximal tubule
Rationale:Canagliflozin is an SGLT2 inhibitor that blocks glucose reabsorption in the kidney,
causing glucosuria and lowering plasma glucose. It does not stimulate insulin secretion, act
on PPAR (thiazolidinediones), or activate AMP kinase (metformin).
Q6.
A patient is receiving IV heparin and develops a platelet count drop to 50,000/µL. Which
test is most specific for confirming heparin-induced thrombocytopenia?
A. Serotonin release assay B. Platelet factor 4/heparin ELISA
C. Complete blood count with peripheral D. Prothrombin time and INR
smear
Page 4
BUNDLE | QUESTIONS & ANSWERS WITH RATIONALES, V1-V3,
DRUG TABLES, DOSAGE CALCULATIONS & 2 MOCK EXAMS
210 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
WGU D398 INTRODUCTION TO PHARMACOLOGY OA STUDY BUNDLE | QUESTIONS & ANSWERS WITH
RATIONALES, V1-V3, DRUG TABLES, DOSAGE CALCULATIONS & 2 MOCK EXAMS. It contains 210 carefully
selected questions that reflect the most current exam content and testing strategies. Each question is
accompanied by a correct answer and a detailed rationale that explains the underlying pathophysiology,
pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 210 Questions
Foundations - Application - WGU D398 Introduction TO Pharmacology OA Study Bundle & WITH
Rationales V1 V3 DRUG Tables Dosage Calculations & 2 Exams WGU D398 Introduction TO Pharmacology
OA Study Bundle & WITH Rationales V1 V3 DRUG Tables Dosage Calculations & 2 Exams University
All answers with rationales
,Table of Contents
Content Area Questions Key Topics
Pharmacokinetics AND 1-35 Prescribed, Likely, Warfarin, Effect, Receiving
Pharmacodynamics
Autonomic Nervous System 36-70 Appropriate, Mechanism, Diabetes, Develops, Prescribed
Drugs
Cardiovascular AND Renal 71-105 Mechanism, Effect, Prescribed, Likely, Ratio
Drugs
Central Nervous System 106-140 Prescribed, Effect, Digoxin, Mechanism, Laboratory
Drugs
Endocrine Drugs 141-175 Effect, Prescribed, Concentration, Likely, Phenytoin
Antimicrobials AND 176-210 Likely, Develops, Explains, Mechanism, Adverse
Anti-infectives
TOTAL 210 All questions include answers and detailed rationales
,Section A - Pharmacokinetics AND Pharmacodynamics
Q1.
A patient on an SSRI for major depression develops serotonin syndrome after adding
linezolid. Which pharmacodynamic principle best explains this interaction?
A. Competitive antagonism at 5-HT3 B. Irreversible inhibition of monoamine
receptors oxidase leading to excess synaptic
serotonin
C. Cytochrome P450 2D6 inhibition D. Displacement of serotonin from plasma
increasing SSRI levels proteins
Correct: B - Irreversible inhibition of monoamine oxidase leading to excess synaptic
serotonin
Rationale:Linezolid is a reversible, nonselective MAO inhibitor that decreases serotonin
metabolism, and when combined with an SSRI, it can precipitate serotonin syndrome. This is
a pharmacodynamic interaction at the enzyme level, not receptor antagonism or
pharmacokinetic CYP inhibition. Protein binding displacement is not a significant mechanism
for this interaction.
Q2.
A prescriber orders a loading dose of digoxin followed by maintenance therapy. Which
pharmacokinetic parameter is most critical to calculate the loading dose?
A. Clearance B. Volume of distribution
C. Half-life D. Bioavailability
Correct: B - Volume of distribution
Rationale:The loading dose is calculated as target concentration multiplied by volume of
distribution divided by bioavailability. Clearance and half-life determine maintenance dosing
and time to steady state, not the initial loading dose. Bioavailability is a modifier but not the
primary determinant.
Q3.
A patient with opioid-induced constipation is prescribed methylnaltrexone. Which
property of this drug makes it peripherally selective?
A. It is a highly lipophilic agonist that B. It is a quaternary amine that poorly
crosses the blood-brain barrier penetrates the central nervous system
C. It is a prodrug activated only in the gut D. It is a substrate for P-glycoprotein efflux
in the brain
Page 3
, Section A - Pharmacokinetics AND Pharmacodynamics
Correct: B - It is a quaternary amine that poorly penetrates the central nervous system
Rationale:Methylnaltrexone is a quaternary ammonium compound with low lipophilicity,
limiting CNS penetration, thus it antagonizes peripheral opioid receptors without reversing
analgesia. It is not an agonist, not a prodrug, and P-glycoprotein is not the primary
mechanism.
Q4.
A patient on warfarin requires a course of an antibiotic. Which antibiotic is most likely to
increase warfarin's anticoagulant effect through inhibition of CYP2C9?
A. Azithromycin B. Ciprofloxacin
C. Metronidazole D. Cephalexin
Correct: C - Metronidazole
Rationale:Metronidazole is a potent inhibitor of CYP2C9, the enzyme that metabolizes
S-warfarin, leading to increased INR and bleeding risk. Ciprofloxacin inhibits CYP1A2 and
3A4, but its effect on warfarin is less pronounced. Azithromycin has minimal CYP inhibition,
and cephalexin is not known to interact significantly.
Q5.
A patient with type 2 diabetes is prescribed canagliflozin. Which mechanism of action is
correct for this drug?
A. Increases insulin secretion from B. Inhibits sodium-glucose cotransporter 2 in
pancreatic beta cells the proximal tubule
C. Activates peroxisome D. Decreases hepatic glucose production by
proliferator-activated receptor gamma activating AMP kinase
Correct: B - Inhibits sodium-glucose cotransporter 2 in the proximal tubule
Rationale:Canagliflozin is an SGLT2 inhibitor that blocks glucose reabsorption in the kidney,
causing glucosuria and lowering plasma glucose. It does not stimulate insulin secretion, act
on PPAR (thiazolidinediones), or activate AMP kinase (metformin).
Q6.
A patient is receiving IV heparin and develops a platelet count drop to 50,000/µL. Which
test is most specific for confirming heparin-induced thrombocytopenia?
A. Serotonin release assay B. Platelet factor 4/heparin ELISA
C. Complete blood count with peripheral D. Prothrombin time and INR
smear
Page 4
